Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04804033 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1,753
- Enrollment target
NCT04804033: Clinical Trial Phase 2 study, sponsored by Pfizer.
NCT04804033 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 1,753 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (1218% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04804033, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1,753 participants
- Enrollment target
Study Summary
The purpose of this is study is to compare the efficacy of BHV-3500 (zavegepant) to placebo as a preventive treatment for migraine, as measured by the reduction in the number of migraine days per month.
Primary Outcome
A migraine day was defined as any calendar day in which participant experienced a qualified migraine headache (onset, continuation or recurrence of migraine headache). A qualified migraine headache was defined as migraine with or without aura, lasting for greater than or equal to (\>=) 30 minutes, and met at least one of the following criteria (A and/or B): A. \>=2 of the following pain features: a. Unilateral location, b. Pulsating quality (throbbing), c. Moderate or severe pain intensity, d. A
Interventions
- DRUG Placebo
- DRUG BHV-3500 (zavegepant)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,753 participants |
| Start Date | 2021-03-26 |
| Est. Completion | 2024-03-21 |
| Phase | Phase 2 |
Why NCT04804033 stopped before completion
NCT04804033 is an interventional study that assigns participants to a tested intervention. Its 1,753 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (1218% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04804033 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04804033 about?
NCT04804033 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention". The purpose of this is study is to compare the efficacy of BHV-3500 (zavegepant) to placebo as a preventive treatment for migraine, as measured by the reduction in the number of migraine days per month.
What is the current status of trial NCT04804033?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1,753 participants. The study started on 2021-03-26. Estimated completion is 2024-03-21.
What interventions are being tested in trial NCT04804033?
The interventions under investigation include: Placebo (DRUG), BHV-3500 (zavegepant) (DRUG).
Who is sponsoring clinical trial NCT04804033?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04804033's enrollment target sits among peer trials
1,753 11th of 2000 higher than 1,990 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07062172 · 1,753 participants · NA
Lung Cancer Screening of Family Members of Patients With Mutation-Driven Lung Cancer
- NCT06872892 · 1,755 participants · Phase 3
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
- NCT05934487 · 1,750 participants · NA
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
- NCT06954337 · 1,750 participants · NA
MATCH-UP: MAking Telehealth-Delivery of Cancer Care at Home Effective and Safe-Upscaled: A Pragmatic Cluster Randomized Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI